ForMune, a Navarra, Spain-based newly created developer of molecules for subsequent license to pharmaceutical companies and / or marketing, has raised €4.4m in funding.
Founding investors include Navarra Development Society (Sodena) and venture capital firms Inveready and Caja Navarra.
Set up as a spin-off of Digna Biotech, ForMune has licensed a new technology for the development of therapeutic vaccines based on protein Extra Domain A (EDA) of fibronectin.
The company intends to use the capital, which will provided over the next three years, to pursue the development of a therapy for the treatment of neck uterine cancer caused by human papillomavirus (HPV), and liver infections of Hepatitis B virus (HBV ).
FinSMEs
19/09/2012